IDL Biotech AB has appointed a new CEO | IDL Biotech
IDL Biotech

CLOSE MENU

Articles

Latest News

November 2020

IDL Biotech AB has appointed a new CEO

Gunnar Wahlberg was appointed as the new CEO of IDL Biotech from the 1st of December 2020. Gunnar has served as acting CEO since the 1st of September after the previous CEO left the post on the 31st of August. Gunnar Wahlberg has previously been a part of IDL Biotech group executive board and worked as Head of Sales since spring of 2019.

Read the press release here (in Swedish)

IDL Biotech includes additional clinics in its ongoing multicenter study for UBC® Rapid in Sweden.

IDL Biotech currently has a number of ongoing clinical studies both internationally and in Sweden, with the aim of demonstrating the clinical benefit of UBC® Rapid in bladder cancer and having the test included as a complement in the follow-up of patients with bladder cancer who are classified as high risk.

IDL Biotech signs distributor agreements in Rwanda, South Sudan and Somalia

IDL Biotech continues to expand in Africa. Today, IDL Biotech has signed a distributor agreement with Roi Scientific Ltd covering Rwanda, South Sudan and Somalia. The agreement covers the sale of TUBEX® TF.

IDL Biotech

Skip this intro